ADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million

Reuters

Jan 09

ADC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million

ADC Therapeutics SA reported preliminary, unaudited net product revenue of approximately $22 million for the fourth quarter of 2025 and $73 million for the full year 2025. This represents a slight increase from the $69.3 million in net product revenue recorded in full year 2024. The fourth quarter 2025 revenue also rose compared to $16.4 million in the same period of the previous year, primarily due to variability in customer ordering. The company noted that underlying demand for ZYNLONTA in its current indication remained broadly stable year-over-year. ADC Therapeutics ended 2025 with about $261 million in cash and cash equivalents, and expects this will support operations at least through 2028. The company anticipates an acceleration in net product revenue growth beginning in 2027, pending clinical and regulatory developments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59388) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2602318680"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602318680\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602318680?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602318680","market":"nz","top_or_hot":-1,"title":"ADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> reported preliminary, unaudited net product revenue of approximately $22 million for the fourth quarter of 2025 and $73 million for the full year 2025. This represents a slight increase from the $69.3 million in net product revenue recorded in full year 2024. The fourth quarter 2025 revenue also rose compared to $16.4 million in the same period of the previous year, primarily due to variability in customer ordering. The company noted that underlying demand for ZYNLONTA in its current indication remained broadly stable year-over-year. ADC Therapeutics ended 2025 with about $261 million in cash and cash equivalents, and expects this will support operations at least through 2028. The company anticipates an acceleration in net product revenue growth beginning in 2027, pending clinical and regulatory developments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59388) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> reported preliminary, unaudited net product revenue of approximately $22 million for the fourth quarter of 2025 and $73 million for the full year 2025. This represents a slight increase from the $69.3 million in net product revenue recorded in full year 2024. The fourth quarter 2025 revenue also rose compared to $16.4 million in the same period of the previous year, primarily due to variability in customer ordering. The company noted that underlying demand for ZYNLONTA in its current indication remained broadly stable year-over-year. ADC Therapeutics ended 2025 with about $261 million in cash and cash equivalents, and expects this will support operations at least through 2028. The company anticipates an acceleration in net product revenue growth beginning in 2027, pending clinical and regulatory developments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59388) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADCT","symbol_name":"ADC Therapeutics SA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL60VtsX:1","article_id":"2602318680","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602318680","pubTimestamp":1767906379,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ADC Therapeutics SA reported preliminary, unaudited net product revenue of approximately $22 million for the fourth quarter of 2025 and $73 million for the full year 2025. This represents a slight increase from the $69.3 million in net product revenue recorded in full year 2024. The fourth quarter 2025 revenue also rose compared to $16.4 million in the same period of the previous year, primarily due to variability in customer ordering. The company noted that underlying demand for ZYNLONTA in its current indication remained broadly stable year-over-year. ADC Therapeutics ended 2025 with about $261 million in cash and cash equivalents, and expects this will support operations at least through 2028. The company anticipates an acceleration in net product revenue growth beginning in 2027, pending clinical and regulatory developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADCT":"ADC Therapeutics SA","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"ADC Therapeutics预计到2028年现金跑道，2025年收入为7300万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADCT":0.9},"content_text":"ADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million\n    \n\nADC Therapeutics SA reported preliminary, unaudited net product revenue of approximately $22 million for the fourth quarter of 2025 and $73 million for the full year 2025. This represents a slight increase from the $69.3 million in net product revenue recorded in full year 2024. The fourth quarter 2025 revenue also rose compared to $16.4 million in the same period of the previous year, primarily due to variability in customer ordering. The company noted that underlying demand for ZYNLONTA in its current indication remained broadly stable year-over-year. ADC Therapeutics ended 2025 with about $261 million in cash and cash equivalents, and expects this will support operations at least through 2028. The company anticipates an acceleration in net product revenue growth beginning in 2027, pending clinical and regulatory developments.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59388) on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}